减重市场狂飙,GLP-1RAs 催生新“药王”。25Q1,全球主要GLP-1RAs(GLP-1R 激动剂)药物销售额达159.6 亿美元,同比增长47.9%,其中减重领域增速远超降糖领域。25Q1 司美格鲁肽销售额达83.8 亿美元,超过帕博利珠单抗成为新“药王”。值得注意的是,25Q1 替尔泊肽销售额已达61.5 亿美元,同比增速远超司美格鲁肽,2025 全年销售额有望登顶。开发趋势:从单纯追求...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.